Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
11 06 2019
Historique:
received: 07 01 2019
revised: 06 03 2019
accepted: 07 03 2019
entrez: 8 6 2019
pubmed: 7 6 2019
medline: 28 3 2020
Statut: ppublish

Résumé

High systolic blood pressure (SBP) increases cardiac afterload, whereas low diastolic blood pressure (DBP) may lead to impaired coronary perfusion. Thus, wide pulse pressure (high systolic, low diastolic [HSLD]) may contribute to myocardial ischemia and also be a predictor of adverse cardiovascular events. The purpose of this study was to determine the relationship between pre-procedural blood pressure and long-term outcome following percutaneous coronary intervention (PCI). The study included 10,876 consecutive patients between August 2009 and December 2016 from the Melbourne Interventional Group registry undergoing PCI with pre-procedural blood pressure recorded. Patients with ST-segment elevation myocardial infarction, cardiogenic shock, and out-of-hospital cardiac arrest were excluded. Patients were divided into 4 groups according to SBP (high ≥120 mm Hg, low <120 mm Hg) and DBP (high >70 mm Hg, low ≤70 mm Hg). Mean pulse pressure was 60 ± 21 mm Hg. Patients with HSLD were older and more frequently women, with higher rates of hypercholesterolemia, renal impairment, diabetes, and multivessel and left main disease (all p ≤ 0.0001). There was no difference in 30-day major adverse cardiac events, but at 12 months the HSLD group had a greater incidence of myocardial infarction (p = 0.018) and stroke (p = 0.013). Long-term mortality was highest for HSLD (7.9%) and lowest for low systolic, high diastolic (narrow pulse pressure) at 2.1% (p = 0.0002). Cox regression analysis demonstrated significantly lower long-term mortality in the low systolic, high diastolic cohort (hazard ratio: 0.50; 99% confidence interval: 0.25 to 0.98; p = 0.04). Pulse pressure at the time of index PCI is associated with long-term outcomes following PCI. A wide pulse pressure may serve as a surrogate marker for risk following PCI and represents a potential target for future therapies.

Sections du résumé

BACKGROUND
High systolic blood pressure (SBP) increases cardiac afterload, whereas low diastolic blood pressure (DBP) may lead to impaired coronary perfusion. Thus, wide pulse pressure (high systolic, low diastolic [HSLD]) may contribute to myocardial ischemia and also be a predictor of adverse cardiovascular events.
OBJECTIVES
The purpose of this study was to determine the relationship between pre-procedural blood pressure and long-term outcome following percutaneous coronary intervention (PCI).
METHODS
The study included 10,876 consecutive patients between August 2009 and December 2016 from the Melbourne Interventional Group registry undergoing PCI with pre-procedural blood pressure recorded. Patients with ST-segment elevation myocardial infarction, cardiogenic shock, and out-of-hospital cardiac arrest were excluded. Patients were divided into 4 groups according to SBP (high ≥120 mm Hg, low <120 mm Hg) and DBP (high >70 mm Hg, low ≤70 mm Hg).
RESULTS
Mean pulse pressure was 60 ± 21 mm Hg. Patients with HSLD were older and more frequently women, with higher rates of hypercholesterolemia, renal impairment, diabetes, and multivessel and left main disease (all p ≤ 0.0001). There was no difference in 30-day major adverse cardiac events, but at 12 months the HSLD group had a greater incidence of myocardial infarction (p = 0.018) and stroke (p = 0.013). Long-term mortality was highest for HSLD (7.9%) and lowest for low systolic, high diastolic (narrow pulse pressure) at 2.1% (p = 0.0002). Cox regression analysis demonstrated significantly lower long-term mortality in the low systolic, high diastolic cohort (hazard ratio: 0.50; 99% confidence interval: 0.25 to 0.98; p = 0.04).
CONCLUSIONS
Pulse pressure at the time of index PCI is associated with long-term outcomes following PCI. A wide pulse pressure may serve as a surrogate marker for risk following PCI and represents a potential target for future therapies.

Identifiants

pubmed: 31171090
pii: S0735-1097(19)34786-2
doi: 10.1016/j.jacc.2019.03.493
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2846-2855

Investigateurs

Chris Reid (C)
Nick Andrianopoulos (N)
Angela Brennan (A)
Diem Dinh (D)
Chris Reid (C)
Andrew Ajani (A)
Stephen Duffy (S)
David Clark (D)
Melanie Freeman (M)
Chin Hiew (C)
Nick Andrianopoulos (N)
Ernesto Oqueli (E)
Angela Brennan (A)
S J Duffy (SJ)
J A Shaw (JA)
A Walton (A)
A Dart (A)
A Broughton (A)
J Federman (J)
C Keighley (C)
C Hengel (C)
K H Peter (KH)
D Stub (D)
W Chan (W)
J Warren (J)
J O'Brien (J)
L Selkrig (L)
R Huntington (R)
D J Clark (DJ)
O Farouque (O)
M Horrigan (M)
J Johns (J)
L Oliver (L)
J Brennan (J)
R Chan (R)
G Proimos (G)
T Dortimer (T)
B Chan (B)
V Nadurata (V)
R Huq (R)
D Fernando (D)
A Al-Fiadh (A)
M Yudi (M)
H Sugumar (H)
J Ramchand (J)
H Han (H)
S Picardo (S)
L Brown (L)
E Oqueli (E)
C Hengel (C)
A Sharma (A)
B Zhu (B)
N Ryan (N)
T Harrison (T)
G New (G)
L Roberts (L)
M Freeman (M)
M Rowe (M)
G Proimos (G)
Y Cheong (Y)
C Goods (C)
D Fernando (D)
A Teh (A)
S Parfrey (S)
J Ramzy (J)
A Koshy (A)
P Venkataraman (P)
D Flannery (D)
C Hiew (C)
M Sebastian (M)
T Yip (T)
Michael Mok (M)
C Jaworski (C)
A Hutchinson (A)
C Cimenkaya (C)
P Ngu (P)
B Khialani (B)
H Salehi (H)
M Turner (M)
J Dyson (J)
B McDonald (B)
D Van Den Nouwelant (D)
K Halliburton (K)
C Reid (C)
N Andrianopoulos (N)
A L Brennan (AL)
D Dinh (D)
B P Yan (BP)
A E Ajani (AE)
R Warren (R)
D Eccleston (D)
J Lefkovits (J)
R Iyer (R)
R Gurvitch (R)
W Wilson (W)
M Brooks (M)
S Biswas (S)
J Yeoh (J)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. All rights reserved.

Auteurs

Josephine Warren (J)

Alfred Hospital, Melbourne, Victoria, Australia.

Shane Nanayakkara (S)

Alfred Hospital, Melbourne, Victoria, Australia; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.

Nick Andrianopoulos (N)

Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia.

Angela Brennan (A)

Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia.

Diem Dinh (D)

Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia.

Matias Yudi (M)

Austin Hospital, Melbourne, Victoria, Australia.

David Clark (D)

Austin Hospital, Melbourne, Victoria, Australia.

Andrew E Ajani (AE)

Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Christopher M Reid (CM)

Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia.

Laura Selkrig (L)

Alfred Hospital, Melbourne, Victoria, Australia.

James Shaw (J)

Alfred Hospital, Melbourne, Victoria, Australia.

Chin Hiew (C)

Geelong Hospital, Geelong, Victoria, Australia.

Melanie Freeman (M)

Box Hill Hospital, Melbourne, Victoria, Australia.

David Kaye (D)

Alfred Hospital, Melbourne, Victoria, Australia; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.

Bronwyn A Kingwell (BA)

Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Anthony M Dart (AM)

Alfred Hospital, Melbourne, Victoria, Australia; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Stephen J Duffy (SJ)

Alfred Hospital, Melbourne, Victoria, Australia; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia. Electronic address: s.duffy@alfred.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH